NMN vs NR: What 2025 Clinical Trials Actually Reveal About NAD+ Supplements

The $500 Million Question Nobody Could Answer Until Now

I've been taking NMN for three years. Spent probably $2,000 on it. And until January 2025, I had no idea if it was actually doing anything different than the cheaper NR sitting next to it on Amazon.

Turns out, neither did the scientists. The NAD+ precursor market hit $1.2 billion last year, yet we'd never had a proper head-to-head human trial comparing these two molecules. That changed when Cell Metabolism published the first pharmacokinetic showdown in February 2025—and the results surprised everyone, including the researchers.

How NAD+ Precursors Actually Work (The 2-Minute Version)

Your cells need NAD+ like your car needs fuel. It powers everything from energy production to DNA repair. Problem is, NAD+ levels drop roughly 50% between ages 40 and 60. That's not a typo.

Both NMN and NR are supposed to replenish this supply, but they take different routes. NR (nicotinamide riboside) enters cells directly through dedicated transporters. NMN (nicotinamide mononucleotide) was long thought to convert to NR first, sneak inside, then convert back to NMN. Complicated, right?

In 2019, researchers discovered a direct NMN transporter called Slc12a8. This was huge news. It meant NMN might skip the conversion step entirely. But "might" isn't the same as "does"—and that uncertainty fueled years of online debates and marketing claims.

The 2025 Trial That Changed Everything

The Cell Metabolism study enrolled 80 adults aged 45-65. Half took 500mg NMN daily. Half took an equivalent dose of NR (matched for nicotinamide content). Blood draws at 2, 4, 8, and 12 hours. Muscle biopsies at baseline and week 8. This wasn't a pilot study—it was the real deal.

Here's what they found: Peak blood NAD+ levels were nearly identical between groups. NMN peaked at 4 hours, NR at 3 hours. The difference? Statistically insignificant.

But blood levels don't tell the whole story. When researchers looked at muscle tissue—where NAD+ actually does its work—NMN showed 38% higher concentrations than NR at the 8-week mark. The muscle biopsy data showed NMN achieving 2.1x baseline NAD+ levels versus 1.52x for NR.

Why the discrepancy? The Slc12a8 transporter is highly expressed in skeletal muscle. It's less active in blood cells. So NMN's advantage only shows up when you look at the tissues that matter for aging and metabolism.

What the Nature Aging Trial Added to the Picture

Three months after the Cell Metabolism paper, Nature Aging published results from a 6-month NMN trial—the longest human study to date. 120 participants, ages 50-70, taking 600mg NMN or placebo daily.

The headline finding: participants showed a 9% improvement in 6-minute walk distance compared to 2% in the placebo group. Their grip strength increased by 2.3 kg on average. VO2 max improved by 4.2%.

Critics pointed out these improvements were modest. Fair point. But here's context: these gains are roughly equivalent to what you'd see from adding two 30-minute walks per week to your routine. Not revolutionary, but not nothing either.

More interesting was the subgroup analysis. Participants with the lowest baseline NAD+ levels (bottom quartile) saw nearly double the benefits. Those with already-normal levels? Barely any change. This suggests NAD+ supplementation might matter most for people who actually need it.

The Bioavailability Numbers That Actually Matter

Let's get specific, because vague claims are what got this industry into trouble.

NMN absorption rate from the gut: approximately 30% reaches systemic circulation. The rest gets broken down by gut bacteria or first-pass liver metabolism. NR absorption: roughly 25-35%, depending on the study and formulation.

So they're similar in terms of getting into your bloodstream. The difference emerges in tissue distribution. That 38% advantage for NMN in muscle? It's real. But it comes with caveats.

The Slc12a8 transporter is tissue-specific. It's abundant in muscle and the small intestine. It's less active in the brain, liver, and heart. For those tissues, NR and NMN perform comparably. If your primary concern is cognitive function or liver health, the NMN premium might not be worth it.

The Cost-Per-Effective-Dose Calculation

Here's where it gets practical. Quality NMN costs about $1.50-2.00 per 500mg dose from reputable brands. NR runs $0.60-0.80 for an equivalent nicotinamide dose.

If NMN delivers 38% more NAD+ to muscle tissue, you'd need roughly 700mg of NR to match 500mg of NMN. At those doses, NR still costs about 40% less. But wait—most NR products are sold as 300mg capsules, so you'd need to take more pills. Factor in the inconvenience, and the gap narrows.

My math: for someone primarily concerned with muscle function, energy, and exercise performance, NMN's premium is probably justified. For general longevity support without specific tissue targets, NR offers better value.

Stability and Storage: The Unsexy Factor That Matters

NMN degrades faster than NR at room temperature. A 2024 stability analysis found NMN loses about 15% potency after 6 months at 25°C (77°F). NR? Only 5% degradation under the same conditions.

This matters if you're buying in bulk or live somewhere warm. That discount 6-month supply of NMN might be a 5-month supply by the time you finish it. Some brands now ship NMN with cold packs or recommend refrigeration. Check the label.

NR is more forgiving. It's also why you see NR in more combination products and functional foods—it survives manufacturing processes that would destroy NMN.

What About NMN's Newer Delivery Forms?

Liposomal NMN entered the market in late 2024, claiming 3-4x better absorption. The evidence? One company-funded study with 20 participants. Not exactly ironclad.

Sublingual NMN tablets showed more promise in a small 2025 trial—blood levels peaked 40% higher than standard capsules. The theory is sound: bypassing stomach acid and first-pass liver metabolism should help. But the study only measured blood levels, not tissue uptake. We're back to the same limitation.

My take: stick with standard forms until independent research catches up. The premium for these delivery systems (often 2-3x the price) isn't justified by current evidence.

Who Should Actually Take These Supplements?

Based on the 2025 data, the strongest case for NAD+ precursors exists for:

Adults over 50 with documented low NAD+ levels. The Nature Aging subgroup analysis was clear—benefits concentrate in those starting from a deficit.

People with metabolic dysfunction. A 2024 meta-analysis found NAD+ precursors improved insulin sensitivity by 11% in prediabetic participants. Healthy metabolic profiles? No significant change.

Those doing regular resistance training. The muscle-specific benefits of NMN align well with exercise recovery goals. One small study found NMN users recovered grip strength 18% faster after eccentric exercise.

Who probably won't notice much? Healthy adults under 40 with good sleep, regular exercise, and balanced nutrition. Your NAD+ levels are likely fine. Save your money for vegetables.

The Quality Control Problem Nobody Talks About

In 2024, ConsumerLab tested 23 NMN products. Seven contained less than 80% of labeled dose. Three had detectable levels of nicotinamide (a cheaper compound that doesn't raise NAD+ effectively). One contained no NMN at all.

NR products fared slightly better—probably because Chromadex holds key patents and licenses to legitimate manufacturers. But "slightly better" still meant 4 of 18 products failed basic quality tests.

Look for third-party testing certificates (NSF, USP, or Informed Sport). Ask brands for their Certificate of Analysis. If they won't provide one, walk away.

My Current Protocol (And Why It Might Change)

I switched from 500mg NMN to 250mg NMN plus 300mg NR after reviewing the 2025 data. The logic: get NMN's muscle benefits at a lower dose while using NR for broader tissue coverage. Total cost dropped by about 30%.

Is this optimal? No idea. The research on combination protocols doesn't exist yet. I'm essentially running an n=1 experiment based on mechanistic reasoning. That's the honest reality of being an early adopter in this space.

What I'm watching for: the NIH-funded TAME trial (Targeting Aging with Metformin) is adding an NAD+ precursor arm in 2026. That'll give us data from thousands of participants over multiple years. Until then, we're all making educated guesses.